A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab.

Trial Profile

A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2012

At a glance

  • Drugs Cancer vaccine HER-2 neu (Primary) ; Lapatinib
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2012 Status changed from active, no longer recruiting to completed as reportd by ClinicalTrials.gov.
    • 29 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top